0001090872-25-000021
SEC filingAgilent's Notes reveal a $2.0B buyback authorization, $119M remaining, $140M commercial paper, and $52M restructuring liability.
As of April 30, 2025, Agilent held $1.486B in cash and cash equivalents, with total debt of $3.495B ($146M short-term, $3.349B long-term). The company's commercial paper program had $140M outstanding at a weighted average interest rate of 4.62%. Total shareholders' equity stood at $6.136B. The company's $1.5B revolving credit facility remained undrawn. Goodwill totaled $4.474B, with no impairment indicated after the segment reorganization.
The Notes disclose a restructuring liability of $52M as of April 30, 2025, primarily from the FY25 Plan ($56M expense in Q2 FY2025). The company has $40M in outstanding standby letters of credit and bank guarantees. Standard warranty accrual was $28M. No other material purchase commitments or contractual obligations were explicitly disclosed in the Notes section.
Agilent repurchased $255M of common stock (1.997M shares) in H1 FY2025, with $119M remaining under the 2023 repurchase program. A new $2.0B authorization was approved on May 29, 2024, effective August 1, 2024. Dividends totaled $141M ($0.496 per share) for H1 FY2025, a 5.1% increase YoY. Capital expenditures were $211M (6.3% of sales). Net debt increased by $99M, primarily from commercial paper borrowings.
Agilent reports three segments: Life Sciences and Diagnostics Markets ($1.301B revenue, $246M operating income, 18.9% margin), Agilent CrossLab ($1.409B, $452M, 32.1%), and Applied Markets ($639M, $143M, 22.4%). Revenue growth was +6.3% YoY for Life Sciences and Diagnostics Markets, +4.4% for Agilent CrossLab, and -2.7% for Applied Markets. Geographically, Americas contributed $1.347B, Europe $905M, and Asia Pacific $1.097B in H1 FY2025.
For the six months ended April 30, 2025, Agilent generated net cash from operating activities of $652 million, a decline of $166 million (20.3%) compared to $818 million in the same period last year. Net income decreased to $533 million from $656 million, with non-cash charges including depreciation and amortization ($145 million), share-based compensation ($70 million), and asset impairment charges ($15 million) partially offsetting the decline. Notable working capital outflows were driven by an increase in inventory ($41 million), a decrease in accounts payable ($27 million), and a decrease in employee compensation and benefits ($25 million). A significant income tax payment of $248 million, net of refunds, further pressured operating cash flow.
Capital expenditures increased to $211 million, representing a capex intensity (capex as a percentage of CFO) of 32.4%, up from 23.6% in the prior year. Free cash flow (not explicitly stated) would be approximately $441 million if computed as CFO less capex. The company returned $396 million to shareholders via share repurchases ($255 million) and dividends ($141 million), exceeding estimated free cash flow, implying reliance on debt or cash reserves. Investing activities included no significant acquisition outflows (net cash acquired of $4 million). Financing activities were net negative at $296 million, with $100 million in net short-term debt proceeds partially offsetting outflows.
Overall, cash flow quality declined due to working capital drag and higher tax payments, while capex intensity rose sharply.